Isomorphic Labs secures $2.1 billion in Series B funding for AI-driven drug discovery
Here's what it means for you.
This funding marks a pivotal moment in the evolution of AI applications in pharmaceuticals.
What happened
Isomorphic Labs raised $2.1 billion in Series B funding led by Thrive Capital.
The Context
- Isomorphic Labs was formed as an Alphabet company in 2021.
- The funding will be used to expand its in-house platform IsoDDE.
- The company aims to scale its AI model for drug discovery.
Takeaway
The substantial funding positions Isomorphic Labs to potentially revolutionize drug discovery processes and bring innovative treatments to market.
This article was generated by AI from 4 verified sources and reviewed by A47 editorial systems.
Business, investment, entrepreneurship, leadership, and innovation.
"Forbes is known for its coverage of business leaders, market trends, and entrepreneurial ventures with a pro-business editorial stance."
— A47 Editor
Isomorphic Labs’ $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
Isomorphic Labs has successfully raised $2.1 billion, marking a significant milestone in the field of AI drug discovery. The company, which was established as part of Alphabet in 2021, has not disclosed specific drug candidates that may emerge from t...
Tech, science, and startup news including AI.
"Irish tech outlet covering innovation and AI."
— A47 Editor
Alphabet’s Isomorphic Labs raises $2.1bn in Series B funding
Alphabet's Isomorphic Labs has successfully raised $2.1 billion in Series B funding, aimed at accelerating the application of its AI model in drug discovery. This funding round was led by Thrive Capital, following a previous $600 million round in Mar...
Daily AI news: models, tools, and policy.
"Independent outlet tracking the fast pace of AI."
— A47 Editor
Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials
Isomorphic Labs, an AI drug discovery company founded by DeepMind co-founder Demis Hassabis, has successfully raised $2.1 billion in a Series B funding round led by Thrive Capital. This funding will be utilized to enhance its in-house platform, IsoDD...
Curated tech headlines including AI stories.
"Influential aggregator surfacing the day’s top tech/AI links."
— A47 Editor
Isomorphic Labs, an AI-powered drug discovery spinoff from Google DeepMind, raised $2.1B led by Thrive, after raising $600M in its first round in March 2025 (Pritam Biswas/Reuters)
Isomorphic Labs, an AI-driven drug discovery spinoff from Google DeepMind, has successfully raised $2.1 billion in a funding round led by Thrive Capital, following an earlier $600 million round in March 2025. This significant financial boost is aimed...